Top Markets
#1 Black Phoenix Black Phoenix +167.33%
#2 Islamic Coin Islamic Coin +158.08%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +37.67%
#5 Cryptopia Cryptopia +21.67%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +19.21%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.34%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +15.75%
#9 DOVU DOVU +12.80%
#10 Test Test +12.79%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
ARYx Therapeutics, Inc. ARYx Therapeutics, Inc.

ARYx Therapeutics, Inc.

ARYX
Classement en actions #41544
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc.... Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.
Prix de l'action
$0.0005
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$16.73K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange ARYx Therapeutics, Inc. (ARYX)

Catégorie

Healthcare
Bénéfices pour ARYx Therapeutics, Inc. (ARYX)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de ARYx Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour ARYx Therapeutics, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN